Compare Roblox Corp (RBLX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Smith & Nephew plc — how do they compare? Roblox Corp trades at $47.92 (market cap $32.52B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Roblox Corp is far larger — about 2.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Roblox Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 93 Days and Smith & Nephew plc for 121 Days on average.
| RBLX | SNN | |
|---|---|---|
Market Cap | $32.52B | $11.10B |
Volume | 14,552,045 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $138.56 | $37.17 |
52-Week Low | $35.54 | $26.42 |
Typical Hold Time | 93 Days | 121 Days |
Enterprise Value | $31.34B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox (RBLX) trades at $48.74, up 5.02% in the last session, with technical indicators showing bearish momentum despite recent price strength. The company continues to demonstrate strong revenue growth, reaching $4.89 billion in 2025, but remains unprofitable with a net income margin of -17.61%. Recent analyst downgrades from Jefferies highlight concerns about bookings growth, while AI development tools show potential for long-term platform expansion.
The stock faces near-term headwinds from bearish technical signals and valuation concerns, but strong revenue growth and AI innovation provide long-term potential. Key risks include persistent profitability challenges and competitive pressures in the gaming sector, while analyst consensus suggests modest upside to the $50.85 price target.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
